Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H29ClO4 |
| Molecular Weight | 404.927 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
InChI
InChIKey=QMBJSIBWORFWQT-DFXBJWIESA-N
InChI=1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/16356876
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16356876
Chlormadinone acetate (CMA) is a derivative of naturally secreted progesterone that shows high affinity and activity at the progesterone receptor. It has an anti-estrogenic effect and, in contrast to natural progesterone, shows moderate anti-androgenic properties. CMA acts by blocking androgen receptors in target organs and by reducing the activity of skin 5alpha-reductase. It suppresses gonadotropin secretion and thereby reduces ovarian and adrenal androgen production. CMA shows high contraceptive efficacy by inhibiting ovulation due to its ability to suppress or disrupt endogenous gonadotropin secretion and, by this, inhibits follicular growth and maturation. In addition, it suppresses endometrial thickness and increases the viscosity of cervical mucus. Chlormadinone acetate was withdrawn from the market in the USA, but it is still being used in Europe under the name Belara.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16356876 |
3.8 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | BELARA Approved UseBELARA is a hormonal contraceptive. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1597.3 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16904418/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
CHLORMADINONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9685 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16904418/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
CHLORMADINONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16904418/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: ETHINYL ESTRADIOL |
CHLORMADINONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| likely | ||||
| likely | ||||
| yes [IC50 14.2 uM] | ||||
| yes [IC50 16 uM] | ||||
| yes [IC50 20.2 uM] | ||||
| yes [IC50 8.6 uM] | ||||
Page: 15.0 |
yes [Inhibition 50 uM] | |||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. | 2009-03 |
|
| Hormonal contraception: present and future. | 2008-12 |
|
| Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. | 2008-12 |
|
| Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. | 2008 |
|
| Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer. | 2007-01 |
|
| A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study. | 2006-10 |
|
| [Ocular changes after hormone replacement therapy in postmenopausal women. A preliminary report]. | 2005-04 |
|
| In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. | 2004-12-15 |
|
| Effects of progesterone and norethisterone on cephalexin uptake in the human intestinal cell line Caco-2. | 2004-04 |
|
| Impact of different progestins on endometrial vascularisation of postmenopausal women. A retrospective image analysis-morphometric study. | 2003-11-20 |
|
| Vaginal dryness assessment in postmenopausal women using pH test strip. | 2003-05-30 |
|
| [Ultrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment ]. | 2002-06 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15025547
1 tablet (0.03 mg ethinyl estradiol and 2 mg chlormadinone acetate) daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C776
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
||
|
CFR |
21 CFR 216.24
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
92338
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
Chlormadinone acetate
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
D002715
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
m3372
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | Merck Index | ||
|
206-118-0
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
3591
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
100000090550
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
2369
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID6020274
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL110691
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
9324
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
302-22-7
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
0SY050L61N
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
C365
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY | |||
|
SUB01219MIG
Created by
admin on Mon Mar 31 18:45:31 GMT 2025 , Edited by admin on Mon Mar 31 18:45:31 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD